Tissue Repair

Focus: Tissue Repair is a small Sydney-based biotech (1-50 employees) founded in 2012, focused on wound healing and tissue regeneration products across dermatology and rare skin disorders. The company operates as a public entity with a pipeline spanning Phase 1–3 programs in wound care, epidermolysis bullosa, and stroke recovery.

Dermatology

Profile data last refreshed 3h ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Employees

1-50

Total Funding

$7.5M

Open Jobs

About Tissue Repair

AI assessmentNot Hiring

No open roles listed right now. Follow Tissue Repair to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

OTR4132MD

Stroke, Acute

N/A

Clinical Trials (1)

NCT04083001An Open, Study to Assess the Safety of RGTA® (OTR4132) in Patients With Acute Ischemic Stroke (AIS)

N/A

Help build intelligence for Tissue Repair

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline with 12 active programs including Phase 3 asset (CACIPLIQ20 for scars), offering meaningful exposure to clinical development and regulatory strategy.
Focused therapeutic area (wound healing, dermatology, rare skin disease) creates depth of scientific expertise in emerging regenerative medicine.
Small team size enables hands-on involvement across multiple functional areas and faster career development in a startup environment.

Watch Out For

No active job postings and minimal hiring signal; expansion appears limited and career trajectory may plateau without growth capital.
Pre-revenue status with unknown funding, cash position, and financials creates structural uncertainty around long-term viability and compensation stability.
Public listing without clear commercial traction (no marketed products) suggests limited liquidity or market validation; execution risk on pipeline advancement is high.

Generated by Claude from Tissue Repair's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CACIPLIQ20

Epidermolysis Bullosa Dystrophica

N/A

Clinical Trials (1)

NCT06007235CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa

N/A

CACIPLIQ20 and Nonremovable, Windowed, Fiberglass Cast Boot

Foot Ulcer

N/A

Clinical Trials (1)

NCT01474473Efficacy Of CACIPLIQ20 On Diabetic Ulcers In Patients Wearing An Nonremovable, Windowed, Fiberglass Cast Boot

N/A